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Introduction
Vitamin D deficiency is common in patients with cystic fibrosis (CF) and prevalence ranges from 40 to 90%, depending on age and definition of deficiency. [1] [2] [3] [4] The etiology of vitamin D deficiency in CF is multifactorial, including reduced intake, pancreatic insufficiency, poor body fat stores, reduced sunlight exposure, reduced absorption and decreased vitamin D-binding protein 4, 5 . The prevalence of Vitamin D deficiency remains high in CF despite daily supplementation of the vitamin in the diet. 5 Insufficient vitamin D in the body leads to decreased intestinal absorption of calcium, which results in secondary hyperparathyroidism. The elevated parathyroid hormone causes calcium resorption from bone, resulting in bone weakness, skeletal losses, and early osteoporosis. 6 Related to the high rates of vitamin D deficiency, individuals with CF have also been shown to have low bone mineral density and a relatively higher fracture prevalence. 7 In addition to effects on bone health, vitamin D deficiency is associated with an increased risk for the development of autoimmune diseases, cancer, infections, and cardiovascular disease among individuals without CF. 8, 9 There is also evidence to suggest that vitamin D plays a role in modulating the innate immune system, and vitamin D receptors have been found on Th1 cells and macrophages. 10 Vitamin D deficiency has been related to a higher predisposition to more severe respiratory infections in healthy infants and children. [11] [12] [13] In CF, Pseudomonas aeruginosa infection and colonization are important in CF, as they can significantly decrease lung function and increase morbidity and mortality in this population.
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The present study was undertaken to examine the association between vitamin D status and markers of CF-related pulmonary disease including exacerbations, bacterial colonization and pulmonary function. We further studied the impact of various patient-related risk factors on development of vitamin D deficiency in CF.
Material and methods
Study subjects
This retrospective study was performed in the department of pediatrics, SKIMS hospital, Srinagar. Study includes a review of records of 62 cystic fibrosis patients under follow-up of pediatric pulmonology clinic, with age less than 15 years. Our unit uses a protocolized approach for patients with CF; after initial diagnosis is made, patients are put on a close four-weekly follow-up. Microbiological cultures of respiratory secretions are done every three months.
Pulmonary secretions for cultures are retrieved either by active coughing or oropharyngeal swab in case of non-expectorating younger patients. Broncheoalveolar lavage is performed if patients fail to respond to treatment directed at pathogens cultured using the above mentioned methods.
Pulmonary function tests are done yearly in patients above 6 years of age or earlier if patients are cooperative enough for spirometry. All the patients with CF are routinely started on daily vitamin D supplementation (400-800 IU per day). Further, patients with intestinal disease are started on pancreatic enzyme replacement therapy (PERT).
In our study, patients were included if they were diagnosed with CF either by a positive sweat chloride test, defined as a chloride concentration ≥60mmol/l using pilocarpine iontophoresis, or
with two known CFTR mutations positive in presence of a chloride concentration of 30-59mmol/l. CFTR mutations analyzed were ∆F508, 3849+10kbc->T, R560T and R117H.
The study was approved by the hospital ethics committee. Informed consent was obtained from the parents/guardians of the study patients.
Data collection and data elements
The recorded vitamin D levels were measured between January and December 2016. Data 
Results
Patient characteristics and prevalence of vitamin D deficiency
Retrospective data were analyzed for 62 patients aged less than 15 years. Nine patients with pancreatic sufficiency and two patients with liver dysfunction were excluded. Final data were collected for 51 patients. The median (IQR) age of the patients was 60(36-72) months, and 47% patients were females ( 
Vitamin D and markers of CF-related pulmonary disease
There was a significant difference in mean number of exacerbations (in preceding 1 year)
between the vitamin D-sufficient, -insufficient, and -deficient groups 1(1-3.25), 1(1-1.5), and 0(0-1), respectively; P <0.001) ( Table 1) Table 2) .
Discussion
Taking a cut-off of <12ng/ml for vitamin D deficiency as per the consensus recommendation for pediatric age group, 19 we reported a prevalence of 47.1% in our study patients. Although few studies from large CF centers observed that >90% of patients had vitamin D levels <30 ng/mL, recent data suggested a trend toward higher levels. 1, 5 This recent trend has been attributed mainly to greater awareness about vitamin D in CF resulting in additional supplementation. 1 We supplemented our patients with 400 IU of vitamin D daily as per the CF foundation evidencebased guidelines for children. 20 Further, the clinical practice guidelines for preschoolers from the Cystic Fibrosis Foundation were consistent with CF foundation guidelines in terms of daily dosage. 21 However, the reported presence of low vitamin D in our study emphasizes the continued deficiency despite recommended daily supplementation. The Cystic Fibrosis Studies have shown that vitamin D has pleiotropic effects on the immune system and its daily supplementation modulates immune activation in CF in a complex manner. 22 These studies have conflicting results, with only one study reporting a significant positive relationship between vitamin D level and pulmonary function. 4 Further, some studies reported vitamin D deficiency was related to other markers of CF lung disease, such as pulmonary exacerbations and bacterial colonization with P. aeruginosa. 4, 18 We observed a significant difference in the number of pulmonary exacerbations between those with vitamin D levels <20ng/ml and those with vitamin D levels >20ng/ml. The greatest difference was between the vitamin D-sufficient and -deficient groups. McCauley and co-workers observed that the rate of exacerbations for the deficient vitamin D group, aged 15 to 18 years, was 13.1 per 10 patient-years, which was significantly higher than 4.3 per 10 patient-years for the insufficient and sufficient vitamin D groups (P <0.05). 4 They concluded that higher vitamin D levels in children with CF were associated with lower rates of pulmonary exacerbations. 4 The mechanism by which vitamin D may prevent pulmonary exacerbations has been related to protection from viral infections which account for significant cause of pulmonary exacerbations in children with CF. 11, 12, 16 This is important in the management of CF, wherein pulmonary exacerbations at various ages have been shown to negatively impact lung function, increase mortality, and decrease quality of life. 4, 26 However, the median age in our study patients was 60(36-72) months and only two patients were above 10 years of age. There is a possibility that this observation may be skewed as vitamin D deficiency in our study was most prevalent in younger age groups, as opposed to most studies reporting higher deficiency rates with increasing age.
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Our study has some limitations. First, this was a retrospective study from a single center with a small sample size. Second, owing to the smaller patient sample size adjustment for various variables like sex, vitamin D therapy, anthropometry, seasonal variations in vitamin D levels and other similar confounders could not be determined. Further, we excluded patients with sufficient pancreatic function, so our results cannot be generalized to such patients. However, our study has strengths as well. This is the first study that examines the relationship between vitamin D and various markers of CF pulmonary disease in patients receiving routine vitamin D supplements.
We concluded that vitamin D deficiency was highly prevalent in children with CF, even after routine daily supplementation in diet. Further, vitamin D deficiency is associated with a higher rate of pulmonary exacerbations and higher incidence of pulmonary bacterial colonization than 
